American stock markets saw gains on Monday. This happened as oil prices decreased. Concerns about inflation decreased after ...

U.S. stocks closed higher on Monday, as oil prices retreated after the Israel-Iran attacks left crude production and exports ...

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...

Sarepta Therapeutics Inc. plummeted after reporting a second patient died of acute liver failure while being treated with its gene therapy for a rare muscle disorder.The death of the 15-year-old boy ...

To date, over 900 Duchenne patients have been treated with delandistrogene moxeparvovec. "The signal for ALF is exceptionally rare and has only emerged in the non-ambulatory patients," Sarepta's CEO ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

Investors are regaining some appetite for risk amid rising optimism that the conflict won't spill over into a broader ...

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...

Advanced Micro Devices (AMD) stock is on the rise after Piper Sandler analysts lifted their price target for the stock to $140. Sarepta Therapeutics (SRPT) stock plunges after the company reported a ...

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

European shares made cautious gains on Monday, with Gucci -owner Kering leading the pack following a leadership change. The ...

Following a second patient death, Sarepta is temporarily suspending use of Elevidys in non-ambulatory DMD patients, pending ...